JPMorgan Chase & Co. reiterated their neutral rating on shares of Merck KGaA (FRA:MRK) in a research report released on Thursday.

Several other brokerages have also issued reports on MRK. UBS Group set a €120.00 ($148.15) price objective on Merck KGaA and gave the company a buy rating in a research report on Monday, January 8th. Independent Research set a €103.00 ($127.16) price objective on Merck KGaA and gave the company a neutral rating in a research report on Thursday, November 9th. Warburg Research set a €115.00 ($141.98) price objective on Merck KGaA and gave the company a buy rating in a research report on Thursday, November 9th. Berenberg Bank set a €116.00 ($143.21) price objective on Merck KGaA and gave the company a buy rating in a research report on Thursday, November 9th. Finally, Commerzbank set a €103.00 ($127.16) price objective on Merck KGaA and gave the company a neutral rating in a research report on Thursday, November 9th. Twelve equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Merck KGaA presently has an average rating of Hold and an average price target of €102.86 ($126.99).

How to Become a New Pot Stock Millionaire

Merck KGaA (FRA MRK) opened at €78.74 ($97.21) on Thursday. Merck KGaA has a 12-month low of €76.60 ($94.57) and a 12-month high of €115.00 ($141.98). The stock has a market capitalization of $10,210.00 and a P/E ratio of 13.17.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/03/12/merck-kgaa-mrk-stock-rating-reaffirmed-by-jpmorgan-chase-co.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.